Serological Biomarkers in Melanoma

  • Mel ZimanEmail author
  • Michael Millward
  • Robert Pearce
  • Mark Lee
Part of the Current Clinical Pathology book series (CCPATH)


The greatest potential for improvement of outcome for patients with melanoma lies in the prevention of systemic metastasis. One prospect is the detection of circulating melanoma cells as an indicator of potential metastatic disease. The challenge is to determine whether quantification of circulating tumor cells (CTCs) or analysis of their phenotype most accurately predicts patient outcome. In this chapter, we address these issues and describe appropriate techniques that ensure the accuracy of such measures. We also compare methods for isolation, quantification and characterization of CTCs and suggest informative markers for their analysis in the peripheral blood of patients with melanoma.


Melanoma Cell Melanoma Patient Circulate Tumor Cell Immunomagnetic Bead Melanoma Cell Adhesion Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to thank Mr. Peter Matthews for thoughtful discussion and valuable suggestions.


  1. 1.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedGoogle Scholar
  2. 2.
    Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998;16:1103–11.PubMedGoogle Scholar
  3. 3.
    Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15:1476–84.PubMedGoogle Scholar
  4. 4.
    Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172–8.PubMedGoogle Scholar
  5. 5.
    Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374:362–5.PubMedGoogle Scholar
  6. 6.
    Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253:180–204.PubMedGoogle Scholar
  7. 7.
    Michaelson JS, Cheongsiatmoy JA, Dewey F, et al. Spread of human cancer cells occurs with probabilities indicative of a nongenetic mechanism. Br J Cancer. 2005;93:1244–9.PubMedGoogle Scholar
  8. 8.
    Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2004;88:962–7.PubMedGoogle Scholar
  9. 9.
    Chen LL, Blumm N, Christakis NA, Barabasi AL, Deisboeck TS. Cancer metastasis networks and the prediction of progression patterns. Br J Cancer. 2009;101:749–58.PubMedGoogle Scholar
  10. 10.
    Bockhorn M, Jain RK, Munn LL. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol. 2007;8:444–8.PubMedGoogle Scholar
  11. 11.
    Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975;35:512–6.PubMedGoogle Scholar
  12. 12.
    Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3:53–7.PubMedGoogle Scholar
  13. 13.
    Ikuta Y, Nakatsura T, Kageshita T, et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res. 2005;11:8079–88.PubMedGoogle Scholar
  14. 14.
    Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814–23.PubMedGoogle Scholar
  15. 15.
    Ulmer A, Schmidt-Kittler O, Fischer J, et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res. 2004;10:531–7.PubMedGoogle Scholar
  16. 16.
    Ulmer A, Beutel J, Susskind D, et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res. 2008;14:4469–74.PubMedGoogle Scholar
  17. 17.
    Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68.PubMedGoogle Scholar
  18. 18.
    Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006;12:4605–13.PubMedGoogle Scholar
  19. 19.
    Mazzocca A, Carloni V. The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem. 2009;16:1704–17.PubMedGoogle Scholar
  20. 20.
    Van Den Bossche K, Naeyaert JM, Lambert J. The quest for the mechanism of melanin transfer. Traffic. 2006;7:769–78.Google Scholar
  21. 21.
    Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci. 2005;118:4901–12.PubMedGoogle Scholar
  22. 22.
    Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98:1512–20.PubMedGoogle Scholar
  23. 23.
    Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004;48:365–75.PubMedGoogle Scholar
  24. 24.
    Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67:1979–87.PubMedGoogle Scholar
  25. 25.
    Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156:1515–25.PubMedGoogle Scholar
  26. 26.
    Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.PubMedGoogle Scholar
  27. 27.
    Liang S, Slattery MJ, Wagner D, Simon SI, Dong C. Hydrodynamic shear rate regulates melanoma-leukocyte aggregation, melanoma adhesion to the endothelium, and subsequent extravasation. Ann Biomed Eng. 2008;36:661–71.PubMedGoogle Scholar
  28. 28.
    Bartolome RA, Galvez BG, Longo N, et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res. 2004;64:2534–43.PubMedGoogle Scholar
  29. 29.
    Sanz-Moreno V, Gadea G, Ahn J, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008;135:510–23.PubMedGoogle Scholar
  30. 30.
    Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–12.PubMedGoogle Scholar
  31. 31.
    Pittet MJ. Behavior of immune players in the tumor microenvironment. Curr Opin Oncol. 2009;21:53–9.PubMedGoogle Scholar
  32. 32.
    Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34:997–1004.PubMedGoogle Scholar
  33. 33.
    Bockhorn M, Roberge S, Sousa C, Jain RK, Munn LL. Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Res. 2004;64:2469–73.PubMedGoogle Scholar
  34. 34.
    Glinsky GV. Apoptosis in metastatic cancer cells. Crit Rev Oncol Hematol. 1997;25:175–86.PubMedGoogle Scholar
  35. 35.
    Swartz MA, Kristensen CA, Melder RJ, et al. Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br J Cancer. 1999;81:756–9.PubMedGoogle Scholar
  36. 36.
    Mehes G, Witt A, Kubista E, Ambros PF. Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001;159:17–20.PubMedGoogle Scholar
  37. 37.
    Larson CJ, Moreno JG, Pienta KJ, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A. 2004;62:46–53.PubMedGoogle Scholar
  38. 38.
    Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–53.PubMedGoogle Scholar
  39. 39.
    Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–26.PubMedGoogle Scholar
  40. 40.
    Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–84.PubMedGoogle Scholar
  41. 41.
    Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000;6:100–2.PubMedGoogle Scholar
  42. 42.
    Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA. 2002;99:2193–8.PubMedGoogle Scholar
  43. 43.
    Laubli H, Stevenson JL, Varki A, Varki NM, Borsig L. L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res. 2006;66:1536–42.PubMedGoogle Scholar
  44. 44.
    Fuertes MB, Girart MV, Molinero LL, et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-­mediated cytotoxicity. J Immunol. 2008;180:4606–14.PubMedGoogle Scholar
  45. 45.
    Lacreusette A, Nguyen JM, Pandolfino MC, et al. Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene. 2007;26:881–92.PubMedGoogle Scholar
  46. 46.
    Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol. 2008;3:569–85.PubMedGoogle Scholar
  47. 47.
    Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol. 1998;9:419–22.PubMedGoogle Scholar
  48. 48.
    Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26:535–41.PubMedGoogle Scholar
  49. 49.
    Lee RT, Fallarino F, Ashikari A, Gajewski TF. Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res. 2008;18:289–94.PubMedGoogle Scholar
  50. 50.
    Jack A, Boyes C, Aydin N, Alam K, Wallack M. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg Oncol. 2006;15:13–24.PubMedGoogle Scholar
  51. 51.
    Weight RM, Viator JA, Dale PS, Caldwell CW, Lisle AE. Photoacoustic detection of metastatic melanoma cells in the human circulatory system. Opt Lett. 2006;31:2998–3000.PubMedGoogle Scholar
  52. 52.
    Zalaudek I, Horn M, Richtig E, Hodl S, Kerl H, Smolle J. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol. 2003;148:703–8.PubMedGoogle Scholar
  53. 53.
    Koyanagi K, O’Day SJ, Gonzalez R, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005;23:8057–64.PubMedGoogle Scholar
  54. 54.
    Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33:49–54.PubMedGoogle Scholar
  55. 55.
    Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418:823.PubMedGoogle Scholar
  56. 56.
    Waghorne C, Thomas M, Lagarde A, Kerbel RS, Breitman ML. Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res. 1988;48:6109–14.PubMedGoogle Scholar
  57. 57.
    Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 2008;21:39–55.PubMedGoogle Scholar
  58. 58.
    Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–9.PubMedGoogle Scholar
  59. 59.
    Grichnik JM, Burch JA, Schulteis RD, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol. 2006;126:142–53.PubMedGoogle Scholar
  60. 60.
    Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43:935–46.PubMedGoogle Scholar
  61. 61.
    Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol. 2008;26:2890–4.PubMedGoogle Scholar
  62. 62.
    Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res. 2006;12:5606–7.PubMedGoogle Scholar
  63. 63.
    Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–40.PubMedGoogle Scholar
  64. 64.
    Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583–94.PubMedGoogle Scholar
  65. 65.
    Herlyn M. Driving in the melanoma landscape. Exp Dermatol. 2009;18:506–8.PubMedGoogle Scholar
  66. 66.
    Passegue E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nat Med. 2009;15:23.PubMedGoogle Scholar
  67. 67.
    Smalley KS, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. Int J Cancer. 2009;124:1245–50.PubMedGoogle Scholar
  68. 68.
    Vultur A, Herlyn M. Cracking the system: melanoma complexity demands new therapeutic approaches. Pigment Cell Melanoma Res. 2009;22:4–5.PubMedGoogle Scholar
  69. 69.
    Keshet GI, Goldstein I, Itzhaki O, et al. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun. 2008;368:930–6.PubMedGoogle Scholar
  70. 70.
    Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65:9328–37.PubMedGoogle Scholar
  71. 71.
    La Porta C. Cancer stem cells: lessons from melanoma. Stem Cell Rev. 2009;5:61–5.PubMedGoogle Scholar
  72. 72.
    Fusi A, Reichelt U, Busse A, Ochsenreither S, et al. Correlation of stem cell marker nestin expression on circulating melanoma cells with extension of disease and survival [abstract 8551]. J Clin Oncol. 2010;28:15s.Google Scholar
  73. 73.
    Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615–21.PubMedGoogle Scholar
  74. 74.
    Pantel K, Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Semin Cancer Biol. 2001;11:327–37.PubMedGoogle Scholar
  75. 75.
    Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.PubMedGoogle Scholar
  76. 76.
    Koyanagi K, Mori T, O’Day SJ, Martinez SR, Wang HJ, Hoon DS. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006;66:6111–7.PubMedGoogle Scholar
  77. 77.
    Koyanagi K, O’Day SJ, Gonzalez R, et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 2006;12:1137–43.PubMedGoogle Scholar
  78. 78.
    Voit CA, Schafer-Hesterberg G, Kron M, et al. Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival. J Clin Oncol. 2008;26:5742–7.PubMedGoogle Scholar
  79. 79.
    Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. Proc Natl Acad Sci USA. 2004;101:10501–4.PubMedGoogle Scholar
  80. 80.
    Cools-Lartigue JJ, McCauley CS, Marshall JC, et al. Immunomagnetic isolation and in vitro expansion of human uveal melanoma cell lines. Mol Vis. 2008;14:50–5.PubMedGoogle Scholar
  81. 81.
    Weight RM, Dale PS, Viator JA. Detection of circulating melanoma cells in human blood using photoacoustic flowmetry. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:106–9.PubMedGoogle Scholar
  82. 82.
    Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol. 2001;137:325–30.PubMedGoogle Scholar
  83. 83.
    Van der Auwera I, Peeters D, Benoy IH, et al. Circulating tumour cell detection: a direct comparison between the Cell Search System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer. 2010;102:276–84.PubMedGoogle Scholar
  84. 84.
    Palmieri G, Ascierto PA, Perrone F, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol. 2003;21:767–73.PubMedGoogle Scholar
  85. 85.
    Gradilone A, Cigna E, Agliano AM, Frati L. Tyrosinase expression as a molecular marker for investigating the presence of circulating tumor cells in melanoma patients. Curr Cancer Drug Targets. 2010;10:529–38.PubMedGoogle Scholar
  86. 86.
    Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res. 2007;20:80–91.PubMedGoogle Scholar
  87. 87.
    Keilholz U, Goldin-Lang P, Bechrakis NE, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res. 2004;10:1605–12.PubMedGoogle Scholar
  88. 88.
    Reynolds SR, Albrecht J, Shapiro RL, et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res. 2003;9:1497–502.PubMedGoogle Scholar
  89. 89.
    Samija I, Lukac J, Maric-Brozic J, et al. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res. 2010;20:293–302.PubMedGoogle Scholar
  90. 90.
    Koyanagi K, O’Day SJ, Boasberg P, et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010;16:2402–8.PubMedGoogle Scholar
  91. 91.
    Fusi A, Collette S, Busse A, et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009;45:3189–97.PubMedGoogle Scholar
  92. 92.
    Reinhold U, Berkin C, Bosserhoff AK, et al. Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2001;19:1723–7.PubMedGoogle Scholar
  93. 93.
    Gradilone A, Gazzaniga P, Silvestri I, et al. Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. Oncol Rep. 2003;10:217–22.PubMedGoogle Scholar
  94. 94.
    Blaheta HJ, Paul T, Sotlar K, et al. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-­polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow’s tumour thickness. Br J Dermatol. 2001;145:195–202.PubMedGoogle Scholar
  95. 95.
    Thornton CG, Hartley JL, Rashtchian A. Utilizing uracil DNA glycosylase to control carryover contamination in PCR: characterization of residual UDG activity following thermal cycling. Biotechniques. 1992;13:180–4.PubMedGoogle Scholar
  96. 96.
    Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60:2253–7.PubMedGoogle Scholar
  97. 97.
    Voit C, Schoengen A, Schwurzer M, Weber L, Mayer T, Proebstle TM. Detection of regional melanoma metastases by ultrasound B-scan, cytology or tyrosinase RT-PCR of fine-needle aspirates. Br J Cancer. 1999;80:1672–7.PubMedGoogle Scholar
  98. 98.
    Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol. 1999;17:2562–71.PubMedGoogle Scholar
  99. 99.
    Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999;5:1961–5.PubMedGoogle Scholar
  100. 100.
    Nezos A, Lembessis P, Sourla A, Pissimissis N, Gogas H, Koutsilieris M. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med. 2009;47:1–11.PubMedGoogle Scholar
  101. 101.
    Hsieh HB, Marrinucci D, Bethel K, et al. High speed detection of circulating tumor cells. Biosens Bioelectron. 2006;21:1893–9.PubMedGoogle Scholar
  102. 102.
    Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.PubMedGoogle Scholar
  103. 103.
    Steen S, Nemunaitis J, Fisher T, Kuhn J. Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc (Bayl Univ Med Cent). 2008;21:127–32.Google Scholar
  104. 104.
    Kitago M, Koyanagi K, Nakamura T, et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem. 2009;55:757–64.PubMedGoogle Scholar
  105. 105.
    Holan SH, Viator JA. Automated wavelet denoising of photoacoustic signals for circulating melanoma cell detection and burn image reconstruction. Phys Med Biol. 2008;53:N227–36.PubMedGoogle Scholar
  106. 106.
    Mallidi S, Larson T, Tam J, et al. Multiwavelength photoacoustic imaging and plasmon resonance coupling of gold nanoparticles for selective detection of cancer. Nano Lett. 2009;9:2825–31.PubMedGoogle Scholar
  107. 107.
    Bosserhoff AK. Novel biomarkers in malignant melanoma. Clin Chim Acta. 2006;367:28–35.PubMedGoogle Scholar
  108. 108.
    Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 2008;21:27–38.PubMedGoogle Scholar
  109. 109.
    Gogas H, Eggermont AM, Hauschild A, et al. Biomarkers in melanoma. Ann Oncol. 2009;20(Suppl 6):vi8–13.PubMedGoogle Scholar
  110. 110.
    Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem. 2007;53:1206–15.PubMedGoogle Scholar
  111. 111.
    Hoek KS, Schlegel NC, Brafford P, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006;19:290–302.PubMedGoogle Scholar
  112. 112.
    Talantov D, Mazumder A, Yu JX, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11:7234–42.PubMedGoogle Scholar
  113. 113.
    Mandruzzato S, Callegaro A, Turcatel G, et al. A gene expression signature associated with survival in metastatic melanoma. J Transl Med. 2006;4:50.PubMedGoogle Scholar
  114. 114.
    Alonso SR, Tracey L, Ortiz P, et al. A high-­throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 2007;67:3450–60.PubMedGoogle Scholar
  115. 115.
    Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472–82.PubMedGoogle Scholar
  116. 116.
    Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008;27:565–73.PubMedGoogle Scholar
  117. 117.
    Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol. 2009;44:85–97.PubMedGoogle Scholar
  118. 118.
    Orlow SJ, Silvers WK, Zhou BK, Mintz B. Comparative decreases in tyrosinase, TRP-1, TRP-2, and Pmel 17/silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases. Cancer Res. 1998;58:1521–3.PubMedGoogle Scholar
  119. 119.
    Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11:R46.PubMedGoogle Scholar
  120. 120.
    Tewes M, Aktas B, Welt A, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2009;115:581–90.PubMedGoogle Scholar
  121. 121.
    Leidinger P, Keller A, Borries A, et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer. 2010;10:262.PubMedGoogle Scholar
  122. 122.
    Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010;15:673–82.PubMedGoogle Scholar
  123. 123.
    Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev. 2002;28:255–71.PubMedGoogle Scholar
  124. 124.
    Taback B, O’Day SJ, Boasberg PD, et al. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst. 2004;96:152–6.PubMedGoogle Scholar
  125. 125.
    Nakayama T, Taback B, Nguyen DH, et al. Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients. Ann N Y Acad Sci. 2000;906:87–98.PubMedGoogle Scholar
  126. 126.
    Shinozaki M, O’Day SJ, Kitago M, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007;13:2068–74.PubMedGoogle Scholar
  127. 127.
    Daniotti M, Vallacchi V, Rivoltini L, et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer. 2007;120:2439–44.PubMedGoogle Scholar
  128. 128.
    Mori T, O’Day SJ, Umetani N, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol. 2005;23:9351–8.PubMedGoogle Scholar
  129. 129.
    Fujimoto A, O’Day SJ, Taback B, Elashoff D, Hoon DS. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res. 2004;64:4085–8.PubMedGoogle Scholar
  130. 130.
    Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005;37:1047–54.PubMedGoogle Scholar
  131. 131.
    Gupta PB, Mani S, Yang J, Hartwell K, Weinberg RA. The evolving portrait of cancer metastasis. Cold Spring Harb Symp Quant Biol. 2005;70:291–7.PubMedGoogle Scholar
  132. 132.
    White RM, Zon LI. Melanocytes in development, regeneration, and cancer. Cell Stem Cell. 2008;3:242–52.PubMedGoogle Scholar
  133. 133.
    Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med. 2006;12:925–32.PubMedGoogle Scholar
  134. 134.
    McArdle L, Rafferty MM, Satyamoorthy K, et al. Microarray analysis of phosphatase gene expression in human melanoma. Br J Dermatol. 2005;152:925–30.PubMedGoogle Scholar
  135. 135.
    Carreira S, Goodall J, Denat L, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006;20:3426–39.PubMedGoogle Scholar
  136. 136.
    Kubic JD, Young KP, Plummer RS, Ludvik AE, Lang D. Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res. 2008;21:627–45.PubMedGoogle Scholar
  137. 137.
    Plummer RS, Shea CR, Nelson M, et al. PAX3 expression in primary melanomas and nevi. Mod Pathol. 2008;21:525–30.PubMedGoogle Scholar
  138. 138.
    Lang D, Lu MM, Huang L, et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature. 2005;433:884–7.PubMedGoogle Scholar
  139. 139.
    Ziman M, Millward M, Medic S, et al. Blood test for cutaneous malignant melanoma. Proceedings of the 8th anticancer research conference, 2008. Anticancer Res. 2008;28:3552.Google Scholar
  140. 140.
    Palmieri G, Satriano SM, Budroni M, et al. Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer. 2006;6:266.PubMedGoogle Scholar
  141. 141.
    Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Mel Ziman
    • 1
    • 2
    Email author
  • Michael Millward
    • 3
  • Robert Pearce
    • 2
  • Mark Lee
    • 4
  1. 1.School of Pathology and Laboratory MedicineUniversity of Western AustraliaJoondalupAustralia
  2. 2.School of Exercise, Biomedical and Health ScienceEdith Cowan UniversityJoondalupAustralia
  3. 3.School of Medicine and PharmacologyUniversity of Western AustraliaPerthAustralia
  4. 4.Plastic SurgerySir Charles Gairdner HospitalPerthAustralia

Personalised recommendations